Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: Three new cases

Abstract

Get full access to this article

View all access options for this article.

References

Maillart

Louapre

Lubetzki

. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: A valid option? Mult Scler 2014; 20: 505–509.

Outteryck

Ongagna

Brochet

.; BIONAT Network; CFSEP. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: Clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol 2014; 21: 40–48.

Olsson

Achiron

Alfredsson

. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler 2013;19: 1533–1538.

Berger

Aksamit

Clifford

. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80: 1430–1438.

Cohen

Barkhof

Comi

.; TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.